# Predicting Outcome in Adult Patients With Congenital Heart Disease: A Systematic Review and Meta-Analysis on the Predictive Value of NT-proBNP and High-Sensitive Troponin T

**Authors:** Sara Rashki Ghalenoo, Zohreh Mahmoodi

PMC · DOI: 10.1155/ijvm/1210312 · International Journal of Vascular Medicine · 2025-07-03

## TL;DR

This study finds that two blood markers, NT-proBNP and hs-TnT, can help predict heart-related risks in adults with congenital heart disease.

## Contribution

The study provides a meta-analysis showing the combined predictive power of NT-proBNP and hs-TnT in adult congenital heart disease patients.

## Key findings

- Elevated NT-proBNP levels are strongly linked to higher risk of mortality or cardiac events.
- High hs-TnT levels are also associated with increased risk of adverse outcomes.
- Adjusting for confounding factors strengthens the significance of both biomarkers.

## Abstract

Objective: This study is aimed at evaluating the predictive value of high-sensitive cardiac troponin T (hs-TnT), and N-terminal probrain natriuretic peptide (NT-proBNP), for cardiovascular events and/or survival in stable adult congenital heart disease (ACHD) patients.

Methods: A systematic review along with a meta-analysis was done on studies from 2014 to 2024 that examined hs-TnT, NT-proBNP, and their association with cardiac events and/or mortality in adult patients with congenital heart disease. A comprehensive search was conducted across major databases, and studies reporting biomarker levels and relevant outcomes were included. Data on study characteristics and hazard ratios (HRs) were extracted, and pooled estimates were calculated using random-effects meta-analysis, with heterogeneity assessed through the I2 statistic. STATA software was used for data analysis.

Results: A total of five studies, consisting of 1294 adult congenital heart disease (ACHD) patients, were included in this meta-analysis. Elevated NT-proBNP levels were significantly associated with an increased risk of mortality or cardiac events (HR: 2.13; 95% CI: 1.84–2.42), which remained significant after adjustment for confounding factors (adjusted HR: 2.34; 95% CI: 1.55–3.13). Elevated hs-TnT levels were also associated with a higher risk of adverse outcomes (HR: 1.57; 95% CI: 1.36–1.78), with the association remaining significant after adjustment (adjusted HR: 2.65; 95% CI: 1.22–5.76). Sensitivity analysis excluding a study with a lower hs-TnT cut-off further strengthened the association (adjusted HR: 3.03; 95% CI: 0.86–5.21) and reduced heterogeneity.

Conclusion: In conclusion, this meta-analysis shows the prognostic value of both NT-proBNP and hs-TnT in adults with congenital heart disease. Each of these markers offered a distinct but complementary clinical insight. Although methodological differences of the included studies limit direct comparison, our systematic review supports the potential value of incorporating both biomarkers into routine risk assessment.

## Linked entities

- **Diseases:** congenital heart disease (MONDO:0005453)

## Full-text entities

- **Diseases:** ACHD (MESH:D006330)
- **Chemicals:** N-terminal probrain natriuretic peptide (-)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12245501/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12245501/full.md

## References

32 references — full list in the complete paper: https://tomesphere.com/paper/PMC12245501/full.md

---
Source: https://tomesphere.com/paper/PMC12245501